ATE497775T1 - USE OF A COMBINATION OF CYCLOSPORINE AND PEGYLATED INTERFERONS FOR THE TREATMENT OF HEPATITIS C (HCV) - Google Patents

USE OF A COMBINATION OF CYCLOSPORINE AND PEGYLATED INTERFERONS FOR THE TREATMENT OF HEPATITIS C (HCV)

Info

Publication number
ATE497775T1
ATE497775T1 AT05759733T AT05759733T ATE497775T1 AT E497775 T1 ATE497775 T1 AT E497775T1 AT 05759733 T AT05759733 T AT 05759733T AT 05759733 T AT05759733 T AT 05759733T AT E497775 T1 ATE497775 T1 AT E497775T1
Authority
AT
Austria
Prior art keywords
hcv
cyclosporine
hepatitis
treatment
combination
Prior art date
Application number
AT05759733T
Other languages
German (de)
Inventor
Catherine Cornu-Artis
Guylaine Vachon
Yoko Uryuhara
Kazuo Asakawa
Reinhild Elisabeth Mertes
Shinsyou Yoshiba
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE497775T1 publication Critical patent/ATE497775T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A method of treating a patient having a HCV infection which method comprises administering to said patient a cyclosporin A or a cyclosporin A derivative in association with a conjugate of interferon to a water-soluble polymer in an amount effective to alleviate or eliminate one or more of the signs or symptoms of HCV.
AT05759733T 2004-07-14 2005-07-13 USE OF A COMBINATION OF CYCLOSPORINE AND PEGYLATED INTERFERONS FOR THE TREATMENT OF HEPATITIS C (HCV) ATE497775T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04016583 2004-07-14
PCT/EP2005/007633 WO2006005610A1 (en) 2004-07-14 2005-07-13 Use of a combination of cyclosporine and pegylated interferon for treating hepatitis c (hcv)

Publications (1)

Publication Number Publication Date
ATE497775T1 true ATE497775T1 (en) 2011-02-15

Family

ID=34972493

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05759733T ATE497775T1 (en) 2004-07-14 2005-07-13 USE OF A COMBINATION OF CYCLOSPORINE AND PEGYLATED INTERFERONS FOR THE TREATMENT OF HEPATITIS C (HCV)

Country Status (15)

Country Link
US (1) US7671017B2 (en)
EP (1) EP1778272B1 (en)
JP (1) JP2008506648A (en)
KR (1) KR20070036175A (en)
CN (1) CN1984671A (en)
AT (1) ATE497775T1 (en)
AU (1) AU2005261868B2 (en)
BR (1) BRPI0513370A (en)
CA (1) CA2573207C (en)
DE (1) DE602005026294D1 (en)
ES (1) ES2359925T3 (en)
MX (1) MX2007000503A (en)
PL (1) PL1778272T3 (en)
RU (1) RU2394589C2 (en)
WO (1) WO2006005610A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7538084B2 (en) 2003-03-17 2009-05-26 Amr Technology, Inc. Cyclosporins
JP2008514702A (en) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド Novel cyclosporine analogues and their pharmaceutical use
JP2008514701A (en) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド Cyclosporine alkyne analogs and their pharmaceutical use
US7196161B2 (en) 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
JP2008515886A (en) 2004-10-06 2008-05-15 エーエムアール テクノロジー インコーポレイテッド Cyclosporine alkynes and their usefulness as medical drugs
EP1931696B1 (en) 2005-09-30 2011-02-16 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine a for the treatment and prevention of viral infection
JP5517454B2 (en) 2005-09-30 2014-06-11 スシネキス インク Methods and pharmaceutical compositions for the treatment and prevention of hepatitis C infection
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
EP2023918B1 (en) 2006-05-19 2011-03-23 Scynexis, Inc. Cyclosporins for the treatment and prevention of ocular disorders
WO2008069917A2 (en) 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
CN102083852A (en) 2008-06-06 2011-06-01 西尼克斯公司 Cyclosporin analogs and their use in the treatment of HCV infections
CA2737376A1 (en) * 2008-09-17 2010-03-25 Boehringer Ingelheim International Gmbh Combination of hcv ns3 protease inhibitor with interferon and ribavirin
CN102257159A (en) * 2008-12-18 2011-11-23 弗·哈夫曼-拉罗切有限公司 Biomarkers for hcv treatment response
EP2376524B1 (en) 2008-12-31 2017-03-15 Cypralis Limited Derivatives of cyclosporin a
KR20110111321A (en) 2009-01-30 2011-10-10 이난타 파마슈티칼스, 인코포레이티드 Cyclosporine analogs for preventing or treating hepatitis C
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
AR075584A1 (en) * 2009-02-27 2011-04-20 Intermune Inc THERAPEUTIC COMPOSITIONS THAT INCLUDE beta-D-2'-DESOXI-2'-FLUORO-2'-C-METHYLYCTIDINE AND A CARDIEX ISOINDOL ACID DERIVATIVE AND ITS USES. COMPOUND.
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
EA201200650A1 (en) 2009-10-30 2012-12-28 Бёрингер Ингельхайм Интернациональ Гмбх COMBINED TREATMENTS OF HEPATITIS C VIRUS, INCLUDING BI201335, INTERFERON-ALPHA AND RIBAVIRIN COURSES
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
JP2013529627A (en) 2010-06-24 2013-07-22 パンメド リミテッド Treatment of hepatitis C virus-related disease using hydroxychloroquine or a combination of hydroxychloroquine and an antiviral agent
WO2012176149A1 (en) 2011-06-23 2012-12-27 Panmed Ltd. Treatment of hepatitis c virus
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
DE202012012955U1 (en) 2011-10-21 2014-07-14 Abbvie Inc. A combination of at least two direct-acting antiviral agents (DAAs) for use in the treatment of HCV
EP2583677A3 (en) 2011-10-21 2013-07-03 Abbvie Inc. Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
WO2014085623A1 (en) 2012-11-28 2014-06-05 Enanta Pharmaceuticals, Inc. Novel [n-me-4-hydroxyleucine]-9-cyclosporin analogues
WO2014122537A2 (en) 2013-02-05 2014-08-14 Genoscience Sa Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin
JP2016538317A (en) 2013-08-26 2016-12-08 エナンタ ファーマシューティカルズ インコーポレイテッド Novel cyclosporine analogues for preventing or treating hepatitis C
US9669095B2 (en) 2014-11-03 2017-06-06 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
EA201892448A1 (en) 2016-04-28 2019-06-28 Эмори Юниверсити ALKYN-CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND RELATED APPLICATION METHODS

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
FI111730B (en) 1990-11-02 2003-09-15 Novartis Ag Process for the preparation of non-immunosuppressive cyclosporins
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5858389A (en) * 1996-08-28 1999-01-12 Shaker H. Elsherbini Squalene is an antiviral compound for treating hepatitis C virus carriers
FR2757521B1 (en) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa NOVEL CYCLOSPORIN DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
JPH1180026A (en) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd Novel immunosuppressants, methods of use and methods of identification thereof
US20030216303A1 (en) * 1998-03-06 2003-11-20 Michael Ambuhl Emulsion preconcentrates containing cyclosporin or a macrolide
GB9811854D0 (en) 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
US6136835A (en) * 1999-05-17 2000-10-24 The Procter & Gamble Company Methods of treatment for viral infections
AU2001295966A1 (en) 2000-10-19 2002-04-29 Fujisawa Pharmaceutical Co. Ltd. Cell damage inhibitor
DE10316735A1 (en) * 2002-04-05 2003-11-20 Viromics Gmbh Inhibiting release, maturation and replication of Flaviviridae family viruses, e.g. for the treatment of hepatitis C virus infections, using proteasome inhibitor such as lactacystine or epoxomicin
GB2391471B (en) * 2002-08-02 2005-05-04 Satishchandra Punambhai Patel Pharmaceutical compositions
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
DK1793844T3 (en) 2004-10-01 2011-03-21 Debiopharm Sa Use of [D-MeAla] 3- [EtVal] 4-cyclosporin for the treatment of hepatitis C infection
WO2006071619A1 (en) 2004-12-23 2006-07-06 Novartis Ag Compositions for hcv treatment

Also Published As

Publication number Publication date
WO2006005610A1 (en) 2006-01-19
EP1778272A1 (en) 2007-05-02
AU2005261868A1 (en) 2006-01-19
AU2005261868B2 (en) 2009-01-15
US7671017B2 (en) 2010-03-02
BRPI0513370A (en) 2008-05-06
MX2007000503A (en) 2007-03-08
US20080138316A1 (en) 2008-06-12
EP1778272B1 (en) 2011-02-09
CA2573207A1 (en) 2006-01-19
JP2008506648A (en) 2008-03-06
RU2394589C2 (en) 2010-07-20
CA2573207C (en) 2013-04-16
KR20070036175A (en) 2007-04-02
CN1984671A (en) 2007-06-20
ES2359925T3 (en) 2011-05-30
RU2007105354A (en) 2008-09-10
PL1778272T3 (en) 2011-07-29
DE602005026294D1 (en) 2011-03-24

Similar Documents

Publication Publication Date Title
ATE497775T1 (en) USE OF A COMBINATION OF CYCLOSPORINE AND PEGYLATED INTERFERONS FOR THE TREATMENT OF HEPATITIS C (HCV)
ATE490778T1 (en) USE OF ÄD-MEALAÜ3-ÄETVALÜ4-CICLOSPORIN FOR THE TREATMENT OF HEPATITIS C INFECTION
EA200700243A1 (en) METHODS OF TREATMENT OF HEPATITIS C
ATE525070T1 (en) SILBINE INCOMPONENT FOR THE TREATMENT OF HEPATITIS
DE602004028841D1 (en) PURIN NUCLEOSIDE FOR THE TREATMENT OF FLAVIVIDRAIC DISEASES, INCLUDING HEPATITIS C
ATE475423T1 (en) IMMUNO-STIMULATING POLYNUCLEOTIDE SEQUENCES FOR USE IN PREVENTING AND TREATING VIRAL DISEASES
NO20073632L (en) Treatment of hepatitis C with interferon-beta in an Asian population
AR021876A1 (en) COMBINATION THERAPY FOR HCV INDUCTION OF RIBAVIRINA - INTERFERON ALFA PEGILADO
WO2006033995A3 (en) Thiazolidin-4-ones having anti-hepatitis b activity
AR045870A1 (en) COMBINATION THERAPY FOR HEPATITIS C VIRUS INFECTION
MXPA02012443A (en) PROFARMACO IN 3 '' OF 2'-DEOXI-BETA-L-NUCLEOSIDOS.
CY1112116T1 (en) METHOD OF PATIENTS 'TREATMENT OF PATIENTS C
NO20064547L (en) Methods for treating HIV infection
RU2010153688A (en) BODY DOSAGE MODE
DE60136381D1 (en) Compositions and Methods for Modulating RSV Infections and Immunity
MXPA02011969A (en) Methods of treating viral diseases with il-18 and il-18 combinations.
UA103158C2 (en) Protein-polymer conjugate and treating method
EA200401618A1 (en) TREATMENT OF HEPATITIS C IN THE ASIAN POPULATION OF BETA-INTERFERON SUBCUTE INTRODUCTION
DK1613340T3 (en) Treatment of aspergillus infections with thymosin alfa 1
DE60235955D1 (en) COMPOSITIONS AND METHODS FOR INCREASING CYTOKINE ACTIVITY AND TREATING THE HYPOTENSION ASSOCIATED WITH THE ADMINISTRATION OF CYTOKINES
UA90477C2 (en) Methods for treating hepatitis c (variants)
ATE544453T1 (en) COMBINATION THERAPIES WITH L-FMAU FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTIONS
EA200601392A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF LIPODYSTROPHY
TW200740455A (en) PEG-IFN alpha and ribavirin for HBV treatment
DE60002172D1 (en) USE OF (1R, 4S) -4- (6-AMINO-9H-PURIN-9-YL) -2-CYCLOPENTEN-1-METHANOL IN HBV

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1778272

Country of ref document: EP